drugset / Trial / NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).
Timeline
- Start
- 2022-07-07
- Primary completion
- 2030-06-28
- Completion
- 2030-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | — | — |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Tamoxifen | Small molecule | — | — |